COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
A new generation of non-steroidal anti-inflammatory drugs has been described that selectively targets the inducible isoform of cyclo-oxygenase, cyclo-oxygenase 2 (COX-2). This isoform is expressed at sites of inflammation, which has led to the speculation that its inhibition could provide all the benefits of current nonsteroidal anti-inflammatory drugs, but without their major side-effects on the gastrointestinal system (which are due to inhibition of COX-1). We have shown that COX-2 (identified by use of specific antibodies) is induced during the resolution of an inflammatory response, inhibition of COX-2 resulting in persistence of the inflammation due to the prevention of the synthesis of a range of anti-inflammatory prostanoids. We propose that there is a third isoform of this enzyme family, COX-3, a proposal that will have implication for the prescription of both existing and new generation anti-inflammatory drugs, and might represent a new therapeutic target.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this report, the authors conclude that the reduction of central nervous system (CNS) PGE 2 synthesis by paracetamol may be mediated through inhibition of a COX enzyme yet to be discovered [33], a notion that has also been predicted by others [34,35].”
From Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action (2021) · cites this paper as [35]
Citations
Cites
Carrageenin-Induced Edema in Hind Paw of the Rat as an Assay for Antiinflammatory Drugs
Winter, C. A., Risley, E. A., & Nuss, G. W. (1962) · Experimental Biology and Medicine · doi:10.3181/00379727-111-27849 · Cited by 5,688
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb
Jiang, J., & Struhl, G. (1998) · Nature · doi:10.1038/35154 · Cited by 1,735
Xie, W. L., Chipman, J. G., Robertson, D. L., Erikson, R. L., & Simmons, D. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.7.2692 · Cited by 1,707
Warner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., & Vane, J. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7563 · Cited by 1,519
Hla, T., & Neilson, K. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7384 · Cited by 1,465
Di Rosa, M., Giroud, J. P., & Willoughby, D. A. (1971) · The Journal of Pathology · doi:10.1002/path.1711040103 · Cited by 1,402
Self-citationInducible cyclooxygenase may have anti-inflammatory properties
Gilroy, D. W., Colville-Nash, P. R., Willis, D., Chivers, J., Paul-Clark, M. J., & Willoughby, D. A. (1999) · Nature Medicine · doi:10.1038/9550 · Cited by 1,242
Self-citationLehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110
Cited by
Thun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
Cyclooxygenase inhibitors – current status and future prospects
Dannhardt, G., & Kiefer, W. (2001) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(01)01197-7 · Cited by 657
The development of COX2 inhibitors
Flower, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1034 · Cited by 459
Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed
Dinarello, C. A. (2004) · Journal of Endotoxin Research · doi:10.1179/096805104225006129 · Cited by 435
Arachidonic Acid Metabolism and Kidney Inflammation
Wang, T., Fu, X., Chen, Q., Patra, J. K., Wang, D., Wang, Z., & Gai, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153683 · Cited by 430
Metadata
- Authors
- Willoughby, D. A., Moore, A. R., & Colville-Nash, P. R.
- Affiliations
- St Bartholomew's Hospital (GB)
- Corresponding author
- Willoughby, Derek A
- ORCID
- Moore, Adrian R
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2000-02
- Volume
- 355
- Issue
- 9204
- Pages
- 646-648
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2120102288
- Cited by
- 298
- References
- 19
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 7 · 2022: 11 · 2021: 13 · 2020: 11 · 2019: 11 · 2018: 7 · 2017: 9 · 2016: 7 · 2015: 6 · 2014: 12 · 2013: 6 · 2012: 15
- FWCI
- 15.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- cyclooxygenase-2, cyclooxygenase-1, COX-2 selective inhibitors, nonsteroidal anti-inflammatory drugs, chronic inflammatory diseases, prostanoids, gastrointestinal adverse effects, inflammation resolution, anti-inflammatory drug targets
- MeSH terms
- Animals, Anti-Inflammatory Agents, Non-Steroidal, Humans, Inflammation, Isoenzymes, Membrane Proteins, Peroxidases, Prostaglandin-Endoperoxide Synthases, Cyclooxygenase Inhibitors, Protein Isoforms, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. https://app.cochat.ai/papers/10.1016/s0140-6736(99)12031-2
- The paper
- Willoughby, D. A., Moore, A. R., & Colville-Nash, P. R. (2000). COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. The Lancet. https://doi.org/10.1016/s0140-6736(99)12031-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.